Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Garetosmab→

Garetosmab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2097125-54-5
Molecular formula
C6472H10004N1712O2024S42
Molecular weight
145500 g/mol
Drug class
Activin A-neutralising human monoclonal antibodyactivin A/ALK2 pathway inhibitor
Mechanism of action
Binds activin A and prevents activation of the abnormal ACVR1/ALK2 signalling pathway implicated in fibrodysplasia ossificans progressiva (FOP), reducing formation of heterotopic bone and disease flare-ups.
Indications / reported uses
  • Reduction of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP) under the US FDA PASATRU indication (approved 19 August 2026)

Sources: US FDA — Pasatru approval announcement, 2026 · FDA Purple Book — PASATRU (garetosmab-grts), original approval 19 August 2026 · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Activin A-neutralising human monoclonal antibody; activin A/ALK2 pathway inhibitor

Mechanism of action

Binds activin A and prevents activation of the abnormal ACVR1/ALK2 signalling pathway implicated in fibrodysplasia ossificans progressiva (FOP), reducing formation of heterotopic bone and disease flare-ups.

General use cases

  • Reduction of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP) under the US FDA PASATRU indication (approved 19 August 2026)

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Garetosmab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Garetosmab Permitted Daily Exposure (PDE) report (the Garetosmab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Garetosmab Occupational Exposure Limit (OEL) report (the Garetosmab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.